The colorectal cancer program.

The colorectal cancer program, Genomic Health and its employees used the same rigorous clinical development strategy and standardized quantitative assay technology for the company Oncotype DX breast cancer test developed. More than 1,800 cancer patients and 760 candidate genes were studied in four clinical studies the genes for the the genes for the Oncotype DX colon cancer assay. The resulting genes were more than 1,200 stage II colon cancer tumor samples from the landmark QUASAR study were examined..

This news release contains forward looking statements under the Private Securities Litigation Reform Act of 1995, including statements regarding the applicability of clinical study results to actual outcomes and the Company’s intentions, the Oncotype DX colon cancer Recurrence Score make available to physicians and patients in early 2013. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, and reported results should not be viewed as an indicator of future performance.600 thousand U.S. Dollars IU School of Medicine researchers earn Susan G. Komen for the Cure Granttime faculty members the Indiana University School of Medicine Research Fellowship on Susan G. Komen for the Cure been Award.

The grants will be for the research offers the highest probability of flows results for that patient during the next decade.

John Foley, David Gilley, and Hiromi Tanaka are excellent among the recipients an unparalleled $ 100,000 in grants stopping by U.S. And international scientific. Assistant professor in the IU School of Medicine of the Department of Anatomy and Cell Biology , and scientists to the the IE Simon Cancer Centre received $ 463,499 aid of his research to cancer cell resistance to drugs and which such as may lead to the Crab develop at another point..